Bleeding Disorders Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Bleeding Disorders Treatment Market is Segmented By Type (Hemophilia A, Hemophilia B, Von Willebrand disease, Others), By Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Antifibrinolytics, Desmopressin, Fibrin sealants, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031 

Bleeding Disorders Treatment Market Overview

The Global Bleeding Disorders Treatment Market reached US$ 5.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 11.2 billion by 2030. The global bleeding disorders treatment market is expected to exhibit a CAGR of 8.4% during the forecast period 2024-2031. The rising preponderance of bleeding disorders, promising repayment guidelines and market developments like product takeoffs, product permissions, unions, investments, alliances and expansion among others are expected to boost the global bleeding disorders treatment market growth in the forecast period. 

The demand for bleeding disorders treatment is increasing due to the rising prevalence of bleeding disorders such as hemophilia and von Willebrand disease. The market is witnessing a surge in demand from the American region. The competitive rivalry is intensifying with major players such as Shire, Novo Nordisk, Pfizer and others actively operating in the market.

Bleeding Disorders Treatment Market Scope

To Know more Insights -  Download Sample

Bleeding Disorders Treatment Market Dynamics

Increasing Product Approvals Drive the Growth Of The Bleeding Disorders Treatment Market

Increasing product approvals are expected to drive the global bleeding disorders treatments market growth in the forecast period. For instance, in May 2023, Centessa Pharmaceuticals’ investigational therapy SerpinPC for individuals with hemophilia B was awarded fast-track designation from the U.S. Food and Drug Administration (FDA).  

Moreover, in April 2023, Novo Nordisk's brand Alhemo product Concizumab was authorized as a prophylactic therapy in Canada for hemophilia B individuals aged 12 and elder who are positive for factor IX inhibitors and require a regular prophylactic to avert bleeds or decrease their commonness. It is the foremost authorization for daily under-the-skin injectable therapy.

The Increasing Efforts To Spread Awareness Are Expected To Present The Global Bleeding Disorders Treatment Market With Growth Opportunities

The increasing efforts to spread awareness about hemophilia and other genetic bleeding disorders are presenting the global bleeding disorders treatment market with lucrative growth opportunities in the upcoming years. 

For instance, in March 2023, the National Hemophilia Foundation (NHF), marking its 75th anniversary, hosted its Start the Conversation movement, promoting families to speak regarding their congenital health, their record with blood or bleeding conditions or congenital counseling. Contributors also began discussions regarding the latest investigation, females’ health and medical marijuana.

The High Cost of Treatment is Estimated to Hamper the Global Bleeding Disorders Treatment Market During the Forecast Period

The high cost of treatment is estimated to hamper the global bleeding disorders treatment market growth in the forecast period. For instance, according to the National Hemophilia Foundation, the moderate yearly expense of clotting factor treatments for an individual with extreme hemophilia is approximately $300,000. Medical costs for an individual with extreme hemophilia, the highly typical type of hemophilia, can be twofold of the mentioned.   

Bleeding Disorders Treatment Market Segment Analysis

The global bleeding disorders treatment market is segmented based on type, drug class, distribution channels and region.

Owing to High Prevalence and Increasing Research Activities, Hemophilia A Bleeding Disorder Type Segment is Estimated to Hold Approximately 34.6%

Hemophilia A is the highly typical extreme form of hemophilia. It impacts solely the male gender. The condition can normally be treated nicely, but the medications understood till now do not aid all of those impacted. The increasing research activities for developing new treatment options for hemophilia are expected to boost segment growth in the forecast period. 

For instance, currently, two noteworthy investigations concerning the Haemophilia Centre of the University Hospital Bonn have been published in the New England Journal of Medicine and Lancet Haematology, symbolizing a new landmark for the therapy of hemophilia. In a clinical phase 3 investigation with the participation of the Haemophilia Centre of the University Hospital Bonn (UKB), a unique medication, Efanesoctocog Alpha, has now been investigated for the therapy of hemophilia A for the foremost time.

Source: DataM Intelligence Analysis (2023)

Bleeding Disorders Treatment Market Geographical Share

North America is Estimated to Hold Approximately 38.8% of the Market Share by 2030, Owing to the Increasing Prevalence and Initiatives in This Region

Owing to the growing prevalence of bleeding disorders and increasing initiatives from government organizations in the fight against bleeding disorders in North America the region is estimated to dominate the global bleeding disorders treatment market.

For instance, according to the World Federation of Hemophilia, in the United States solely there are about 18000 individuals with hemophilia and more than 11000 with von Willebrand disorder. Additionally, Hemophilia A impacts 1 in 5,000 male births and roughly 400 newborns are born with hemophilia A per year.

Moreover, in May 2023, the Centers for Disease Control and Prevention discharged a new digital toolkit to boost awareness of bleeding disorders in teens and tweens. The toolkit comprises shareable pictures and samples of social media posts to support tweens and teens who may carry a bleeding condition to comprehend their signs and sense entrusted to come out for support.

Source: DataM Intelligence Analysis (2023)

Bleeding Disorders Treatment Market Companies

The major global players in the bleeding disorders treatment market include Amring Pharmaceuticals Inc., Ferring B.V., Pfizer Inc., Baxter, Nufactor, Takeda Pharmaceuticals U.S.A., Inc., CSL Behring LLC, Grifols Biologicals Inc., Octapharma AG and Novo Nordisk A/S, among others. 

COVID-19 Impact on Bleeding Disorders Treatment Market

Russia-Ukraine Conflict Analysis

The Russia-Ukraine dispute is assessed to hold an average influence on the global bleeding disorders treatment market, because of the inferior preponderance and absence of essential market participants in this region. 

Nevertheless, continuing to countenance attacks from Russian armies, Ukrainian hospitals are forced by advancing numerals of casualties and restricted medical resources. There are shortages across all types of medication. Furthermore, the impact of the import and export of basic materials are expected to have a slight impact on the global bleeding disorders treatment market growth over the forecast period.

By Type

• Hemophilia A
• Hemophilia B
• Von Willebrand disease
• Others

By Drug Class

• Plasma Derived Coagulation Factor Concentrates
  • Factor VIII
  • Factor IX
  • The factor for Von Willebrand Disease
  • Activated Prothrombin Complex Concentrate
• Recombinant Coagulation Factor Concentrates
  • Factor VIII
  • The factor for Von Willebrand Disease
  • Factor IX
• Desmopressin
• Antifibrinolytics
  • Amicar
  • Aminocaproic acid
  • Aprotinin
  • Cyklokapron
  • Fibryga
  • Others
• Fibrin sealants
• Others

By Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In November 2022, the U.S. Food and Drug Administration authorized Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the therapy of grown-ups with Hemophilia B (congenital Factor IX deficiency) who presently utilize Factor IX prophylaxis treatment, or have recent or historical life-threatening bleeding, or have recounted, severe unexpected bleeding outbreaks.
• In February 2023, Efanesoctocog alfa, Sobi, a multinational biopharmaceutical corporation and Sanofi, a French global pharmaceutical and healthcare corporation’s first-in-class, long-lasting recombinant or man-made factor VIII (FVIII) substitute treatment, has been authorized by the U.S. Food and Drug Administration (FDA) for the therapy of hemophilia A
• In April 2023, Xoma, a biotechnology royalty aggregator, completed a $9.6 Billion agreement to purchase from Aptevo Therapeutics the privileges to obtain a revenue stream for deals of Ixinity (trenonacog alfa), an authorized drug utilized to avert and treat bleeding outbreaks in individuals with hemophilia B.

Why Purchase the Report?

• To visualize the global bleeding disorders treatment market segmentation based on type, drug class, distribution channels and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of bleeding disorders treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Bleeding Disorders Treatment Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.

Target Audience 2023

• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies